tradingkey.logo

Bluejay Diagnostics Inc

BJDX
1.790USD
+0.010+0.56%
Close 11/04, 16:00ETQuotes delayed by 15 min
2.67MMarket Cap
LossP/E TTM

Bluejay Diagnostics Inc

1.790
+0.010+0.56%

More Details of Bluejay Diagnostics Inc Company

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Bluejay Diagnostics Inc Info

Ticker SymbolBJDX
Company nameBluejay Diagnostics Inc
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 10
Address360 Massachusetts Avenue, Suite 203
CityACTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01720
Phone19786310152
Websitehttps://bluejaydx.com/
Ticker SymbolBJDX
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey

Company Executives of Bluejay Diagnostics Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--

Revenue Breakdown

FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data

Shareholding Stats

Updated: Sat, Oct 18
Updated: Sat, Oct 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
10.48%
Sabby Management, LLC
5.75%
Armistice Capital LLC
0.42%
Geode Capital Management, L.L.C.
0.25%
L1 Capital Global Opportunities Master Fund Ltd.
0.16%
Other
82.93%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
10.48%
Sabby Management, LLC
5.75%
Armistice Capital LLC
0.42%
Geode Capital Management, L.L.C.
0.25%
L1 Capital Global Opportunities Master Fund Ltd.
0.16%
Other
82.93%
Shareholder Types
Shareholders
Proportion
Corporation
10.68%
Investment Advisor/Hedge Fund
6.00%
Hedge Fund
0.55%
Individual Investor
0.04%
Investment Advisor
0.03%
Research Firm
0.01%
Other
82.69%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
110.14K
6.60%
+88.99K
2025Q2
29
13.33K
0.89%
-11.23K
2025Q1
33
13.32K
1.15%
-11.19K
2024Q4
33
13.25K
2.40%
-10.14K
2024Q3
34
31.07K
8.08%
+26.51K
2024Q2
34
7.19K
9.21%
+4.96K
2024Q1
32
2.22K
59.41%
+553.00
2023Q4
32
1.63K
54.54%
+399.00
2023Q3
33
1.19K
46.18%
+12.00
2023Q2
32
1.16K
61.50%
-18.00
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
96.03K
6.43%
+96.03K
--
Jun 30, 2025
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
4.20K
0.28%
--
--
Aug 31, 2025
L1 Capital Global Opportunities Master Fund Ltd.
2.68K
0.18%
+2.68K
--
Jun 27, 2024
Tower Research Capital LLC
2.27K
0.15%
+533.00
+30.65%
Jun 30, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
UBS Financial Services, Inc.
444.00
0.03%
-368.00
-45.32%
Jun 30, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Citi Investment Research (US)
241.00
0.02%
+241.00
--
Jun 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Date
Type
Ratio
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
Jul 21, 2023
Merger
20→1
View more
KeyAI